WO2002068056A3 - Combination comprising a 1,4-dioxonaphathalene compound and ribenoside - Google Patents

Combination comprising a 1,4-dioxonaphathalene compound and ribenoside Download PDF

Info

Publication number
WO2002068056A3
WO2002068056A3 PCT/GB2002/000791 GB0200791W WO02068056A3 WO 2002068056 A3 WO2002068056 A3 WO 2002068056A3 GB 0200791 W GB0200791 W GB 0200791W WO 02068056 A3 WO02068056 A3 WO 02068056A3
Authority
WO
WIPO (PCT)
Prior art keywords
compound
combination
ribenoside
dioxonaphathalene
tribenoside
Prior art date
Application number
PCT/GB2002/000791
Other languages
French (fr)
Other versions
WO2002068056A2 (en
Inventor
Kim Sze Tan
Joseph Di Chayen
Original Assignee
Ks Biomedix Holdings Plc
Kim Sze Tan
Avron Ann Hf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ks Biomedix Holdings Plc, Kim Sze Tan, Avron Ann Hf filed Critical Ks Biomedix Holdings Plc
Priority to AU2002233539A priority Critical patent/AU2002233539A1/en
Publication of WO2002068056A2 publication Critical patent/WO2002068056A2/en
Publication of WO2002068056A3 publication Critical patent/WO2002068056A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to composition for use in the treatment of inflammatory conditions, such as Rheumatoid Arthritis, and Osteoarthritis (OA), as well as in the treatment of pain. The composition comprise a 1,4-dioxonapthalene compound or pharmaceutically acceptable salt thereof, in combination tribenoside or a tribenoside analogue. In particular the invention relates to a composition, and its uses, comprising tribenoside and menadione bisulphite.
PCT/GB2002/000791 2001-02-23 2002-02-22 Combination comprising a 1,4-dioxonaphathalene compound and ribenoside WO2002068056A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002233539A AU2002233539A1 (en) 2001-02-23 2002-02-22 Combination comprising a 1,4-dioxonaphathalene compound and ribenoside

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0104571.5A GB0104571D0 (en) 2001-02-23 2001-02-23 Composition
GB0104571.5 2001-02-23

Publications (2)

Publication Number Publication Date
WO2002068056A2 WO2002068056A2 (en) 2002-09-06
WO2002068056A3 true WO2002068056A3 (en) 2003-05-15

Family

ID=9909401

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/000791 WO2002068056A2 (en) 2001-02-23 2002-02-22 Combination comprising a 1,4-dioxonaphathalene compound and ribenoside

Country Status (3)

Country Link
AU (1) AU2002233539A1 (en)
GB (1) GB0104571D0 (en)
WO (1) WO2002068056A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03161448A (en) * 1989-11-20 1991-07-11 Asahi Chem Ind Co Ltd Composition containing oil and fat
WO1992013532A2 (en) * 1991-02-04 1992-08-20 Joseph Chayen Naphthoquinone derivatives for the treatment of chronic inflammation
WO1996018403A1 (en) * 1994-12-16 1996-06-20 Ks Biomedix Ltd. Combined use of diclofenac and tribenoside to treat osteoarthritis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03161448A (en) * 1989-11-20 1991-07-11 Asahi Chem Ind Co Ltd Composition containing oil and fat
WO1992013532A2 (en) * 1991-02-04 1992-08-20 Joseph Chayen Naphthoquinone derivatives for the treatment of chronic inflammation
WO1996018403A1 (en) * 1994-12-16 1996-06-20 Ks Biomedix Ltd. Combined use of diclofenac and tribenoside to treat osteoarthritis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1992, SAIKAWA SATOSHI E.A.: "Pharmaceutical formulations of fat-soluble drugs", XP002226746, Database accession no. 116:28149 *

Also Published As

Publication number Publication date
AU2002233539A1 (en) 2002-09-12
WO2002068056A2 (en) 2002-09-06
GB0104571D0 (en) 2001-04-11

Similar Documents

Publication Publication Date Title
AU2001272849A1 (en) Composition for the treatment of osteoarthritis
WO2002046171A3 (en) Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto
WO2004069152A3 (en) Δ4,5 glycuronidase and uses thereof
SI1465626T1 (en) Pharmaceutical compositions (kit) comprising dihydropyridinone compounds and an immunoregulatory (or an antiinflammatory) agent and their uses
IL172773A0 (en) Formulations for the treatment of arhritis conditions
WO2002046170A8 (en) Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto
BG105880A (en) Compounds useful as anti-inflammatory agents
EP3738591A3 (en) Novel antibacterial agents
MXPA03007514A (en) Composition of hypochlorous acid and its applications.
AP2000001947A0 (en) Novel crystalline forms of an antiviral benzidazole compound.
UA86345C2 (en) Normal;heading 1;heading 2;USE OF OSTEOPROTEGERIN FOR THE PREVENTION AND/OR TREATMENT OF FIBROSIS
CA2343732A1 (en) Substituted .gamma.-phenyl-.delta.-lactones and analogs thereof and uses related thereto
WO2003047558A3 (en) Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors
WO2003002064A3 (en) Fused pyrimidine dhfr inhibitors as antibacterials
AU1843397A (en) Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
CA2474511A1 (en) Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disorders
EP2060255A3 (en) Methods and compositions for prevention and treatment of inflammatory disease, autoimmune disease, and transplant rejection
CA2403352A1 (en) Use of comt inhibitors as analgesics
WO2004039326A3 (en) Propofol with cysteine
WO2000040232A3 (en) Bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
WO2003066022A3 (en) Stable pharmaceutical composition useful for treating gastrointestinal disorders
HUP0301864A2 (en) Phenolate-containing formulation with low freezing point
WO2003048342A3 (en) Liquid yeast compositions
WO2002068056A3 (en) Combination comprising a 1,4-dioxonaphathalene compound and ribenoside
AU2002239438A1 (en) 2,4-hexadienoic acid and derivatives as corrosion inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP